Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working